90104-48-6 (多瑞肽,Glycinamide, L-prolyl-(aR)-a-amino-a-ethylbenzenebutanoyl- (9CI))

多瑞肽;

Glycinamide, L-prolyl-(aR)-a-amino-a-ethylbenzenebutanoyl- (9CI);N-{(2R)-1-[(2-Amino-2-oxoethyl)amino]-1-oxo-2-phenyl-2-butanyl}-L -prolinamide;L-Prolyl-(alphaR)-alpha-amino-alpha-ethylbenzeneacetylglycinamide;(2S)-N-((.ALPHA.R)-.ALPHA.-((CARBAMOYLMETHYL)CARBAMOYL)-.ALPHA.-ETHYLBENZYL)-2-PYRROLIDINECARBOXAMIDE;(2S)-N-((alphaR)-alpha-((Carbamoylmethyl)carbamoyl)-alpha-ethylbenzyl)-2-pyrrolidinecarboxamide.;SCHEMBL2734211;UNII-51K3U6Q5ZN;(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-2-phenylbutan-2-yl]pyrrolidine-2-carboxamide;NS00127116;51K3U6Q5ZN;Doreptide [INN];90104-48-6;Q27260905;Doreptide;PD163243;(2S)-N-((alphaR)-alpha-((Carbamoylmethyl)carbamoyl)-alpha-ethylbenzyl)-2-pyrrolidinecarboxamide;

ZALQKBPFOWAOHH-SUMWQHHRSA-N

1S/C17H24N4O3/c1-2-17(12-7-4-3-5-8-12,16(24)20-11-14(18)22)21-15(23)13-9-6-10-19-13/h3-5,7-8,13,19H,2,6,9-11H2,1H3,(H2,18,22)(H,20,24)(H,21,23)/t13-,17+/m0/s1

O=C([C@@H]1CCCN1)N[C@@](C(NCC(N)=O)=O)(C1C=CC=CC=1)CC